Catheter Precision CFO granted 40,000 stock options
Catheter Precision, Inc. reported that its Chief Financial Officer, Philip J. Anderson, received a grant of stock options covering 40,000 shares of common stock.
Rhea-AI Filing Summary
Catheter Precision, Inc. reported that its Chief Financial Officer, Philip J. Anderson, received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $1.15 per share and expire on March 26, 2036.
The options were awarded as a compensation grant and vest 100% on the 180-day anniversary of the grant date. Following this grant, Anderson holds derivative securities representing rights to acquire 40,000 shares of Catheter Precision common stock through these options.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Options (Right to Buy) | 40,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. Options vest 100% on 180 day anniversary of grant date.
Key Figures
Key Terms
Options (Right to Buy) financial
Grant, award, or other acquisition financial
exercise price financial
vest 100% on 180 day anniversary financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Catheter Precision (VTAK) report for its CFO?
What is the exercise price of the CFO’s Catheter Precision (VTAK) stock options?
When do the CFO’s Catheter Precision (VTAK) options vest and expire?
Is the Catheter Precision (VTAK) CFO’s Form 4 transaction a market buy or sell?
How many derivative securities does the Catheter Precision (VTAK) CFO hold after this grant?
AI-generated analysis. How Rhea-AI works. Not financial advice.